• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Gilead lands new cell therapy for Kite in $225M Arcellx deal

cafead

Administrator
Staff member
  • cafead   Dec 09, 2022 at 11:02: AM
via Gilead Sciences has landed its Kite unit at Arcellx to work on a phase 2 multiple myeloma cell therapy in a deal worth $225 million upfront. The biotech will gain global scale as it gears up for a future showdown against an already approved med from healthcare behemoth Johnson & Johnson and its partner Legend Biotech.

article source
 

<